公开(公告)号：US20210139912A1

公开(公告)日：2021-05-13

申请号：US16771907

申请日：2018-12-12

Applicant: AMGEN INC.

Inventor： Ingrid RULIFSON ,  Justin K. MURRAY ,  Michael OLLMANN ,  Oliver HOMANN

IPC: C12N15/113 ,  A61K31/7105

Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.

公开(公告)号：US20250011779A1

公开(公告)日：2025-01-09

申请号：US18697901

申请日：2022-10-04

Applicant: AMGEN INC.

Inventor： Jiamiao LU ,  Michael OLLMANN ,  Patrick COLLINS ,  Chi-Ming LI ,  Songli WANG

IPC: C12N15/113

Abstract: The present invention relates to compositions and methods for enhancing the gene silencing activity of oligonucleotide compounds. In particular, the invention relates to inhibiting the expression or activity of suppressor proteins, such as RAB18, ZW10, STX18, SCFD2, NAPG, SAMD4B, or VPS37A, to increase the efficacy of ligand-conjugated oligonucleotide compounds in reducing the expression of target genes in a cell.

公开(公告)号：US20230279399A1

公开(公告)日：2023-09-07

申请号：US18007560

申请日：2021-06-03

Applicant: Amgen Inc.

Inventor： Daniel C. H. LIN ,  Michael OLLMANN ,  Justin K. MURRAY ,  Bradley J. HERBERICH ,  Amrita DAS ,  Patrick COLLINS ,  Oliver HOMANN

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/315 ,  C12N2310/11

Abstract: The present invention relates to RNAi constructs for reducing expression of the HSD17B13 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.

公开(公告)号：US20220307022A1

公开(公告)日：2022-09-29

申请号：US17615520

申请日：2020-06-01

Applicant: AMGEN INC.

Inventor： Amrita DAS ,  Bradley J. HERBERICH ,  Justin K. MURRAY ,  Oliver HOMANN ,  Michael OLLMANN ,  Daniel C.H. LIN

IPC: C12N15/113 ,  A61K31/713 ,  A61K31/7105

Abstract: The present invention relates to RNAi constructs for reducing expression of the SCAP gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.

公开(公告)号：US20250154512A1

公开(公告)日：2025-05-15

申请号：US19028462

申请日：2025-01-17

Applicant: AMGEN INC.

Inventor： Ingrid RULIFSON ,  Justin K. MURRAY ,  Michael OLLMANN ,  Oliver HOMANN

IPC: C12N15/113 ,  A61K31/7105

Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.

公开(公告)号：US20230078200A1

公开(公告)日：2023-03-16

申请号：US17783232

申请日：2020-12-08

Applicant: AMGEN INC.

Inventor： Bin WU ,  Michael OLLMANN ,  Oliver HOMANN ,  Yuan CHENG

IPC: C12N15/113 ,  A61P9/10

Abstract: The present invention relates to RNAi constructs for reducing expression of the LPA gene, which encodes apolipoprotein(a), a component of lipoprotein(a) (Lp(a)) particles. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease, peripheral artery disease, stroke, and myocardial infarction, and to reduce serum Lp(a) levels are also described.

公开(公告)号：US20220017906A1

公开(公告)日：2022-01-20

申请号：US17312721

申请日：2019-12-10

Applicant: Amgen Inc.

Inventor： Ingrid RULIFSON ,  Justin K. MURRAY ,  Michael OLLMANN ,  Oliver HOMANN

IPC: C12N15/113

Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.

公开(公告)号：US20210108212A1

公开(公告)日：2021-04-15

申请号：US17080771

申请日：2020-10-26

Applicant: AMGEN INC.

Inventor： Michael OLLMANN ,  Yang LI ,  Jun ZHANG ,  Kaustav BISWAS ,  Oliver HOMANN ,  Leslie P. MIRANDA ,  Justin K. MURRAY ,  Bin WU ,  Oh Kyu YOON ,  John Gordon ALLEN ,  Chawita NETIROJJANAKUL ,  Yuan CHENG

IPC: C12N15/113 ,  A61P9/10 ,  A61P3/06 ,  C07K16/28

Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.

公开(公告)号：US20190309306A1

公开(公告)日：2019-10-10

申请号：US16328221

申请日：2017-08-25

Applicant: AMGEN INC.

Inventor： Michael OLLMANN ,  Yang LI ,  Jun ZHANG ,  Kaustav BISWAS ,  Oliver HOMANN ,  Leslie P. MIRANDA ,  Justin K. MURRAY ,  Bin WU ,  Oh Kyu YOON ,  John Gordon ALLEN ,  Chawita NETIROJJANAKUL ,  Yuan CHENG

IPC: C12N15/113 ,  A61P3/06 ,  A61P9/10 ,  C07K16/28

Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.